Anydaynow - I don't mean to come across rude, I am genuinely interested in how people come to their valuation conclusions cause I am clearly on a whole other wave length.
The research note says that 2591 is worth 4 times Daybue and we know from JP's comments that he is of the same view for the 4 current indications in P2 trials. In fact, he has said that the 4 indications are 4 or 5 times the size of Daybue. Alongside some of the excellent posts of this forum, JP has consistently referenced Reata as a good comparator for Daybue given the similar market size, drug pricing etc.
That being the case, and noting that Reata was sold for $7.2b USD, how do you reach the conclusion that JP will give 2591 away for a meagre $5b USD?
I write the above in good faith - genuinely trying to understand the disconnect between my thoughts on valuation and yours/others.
NEU Price at posting:
$14.73 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)